Compare CLWT & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLWT | GTBP |
|---|---|---|
| Founded | 1971 | 1965 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Professional and commerical equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 8.5M |
| IPO Year | 1997 | N/A |
| Metric | CLWT | GTBP |
|---|---|---|
| Price | $1.20 | $0.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.7K | ★ 2.4M |
| Earning Date | 12-30-2025 | 02-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $14,012,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.08 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.99 | $0.54 |
| 52 Week High | $1.63 | $3.85 |
| Indicator | CLWT | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 56.33 | 51.68 |
| Support Level | $1.13 | $0.65 |
| Resistance Level | $1.23 | $0.75 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 83.33 | 42.81 |
Euro Tech Holdings Co Ltd is a distributor and manufacturer of technology instruments as well as an environmental engineering services provider. It is engaged in the marketing and trading of water and wastewater related process control, analytical and testing instruments, disinfection equipment, supplies, and related automation systems. There are two operating segments of the company. The Trading and manufacturing segment, which is the key revenue driver, includes distribution of water treatment equipment, laboratory instruments, analyzers, test kits, and related supplies and power generation equipment. The Engineering segment includes water and waste-water treatment engineering and air pollution control business. The majority of the revenue is generated from Hong Kong.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.